(redirected from Lisdexamfetamine)
Also found in: Dictionary, Medical, Wikipedia.
Related to Lisdexamfetamine: lisdexamfetamine dimesylate
LDXLisdexamfetamine (aka Lisdexamfetamine Dimesylate; stimulant)
LDXLisdexamfetamine Dimesylate (aka Lisdexamfetamine; stimulant)
LDXLoad Index
LDXLoad X (6502 processor instruction)
LDXLong Distance Extender
LDXLong-Distance Xerox
LDXLogo Design Experts (est. 2000)
LDXLow Density Line
References in periodicals archive ?
Previous medications included lisdexamfetamine, dextroamphetamine/amphetamine, and bupropion.
Among reproductive-aged women who filled any ADHD medication prescription in the given year, the percentage who filled a prescription for mixed amphetamine salts and lisdexamfetamine increased from 2003 to 2015, while the percentage who filled a prescription for methylphenidate and atomoxetine decreased over the same period.
Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges.
Lisdexamfetamine belongs to a family of drugs that stimulate the central nervous systems.
Studies involving lisdexamfetamine showed abstinence achieved in 40% of subjects, far higher than the 15% on placebos, and a likelihood of achieving abstinence 2.
In another study, 157 patients aged 6-17 years with ADHD and well controlled on treatment with lisdexamfetamine dimesylate (Vyvanse) were randomized to continued treatment or drug withdrawal.
Lisdexamfetamine, the central nervous system stimulant marketed as Vyvanse, has been approved for treating binge-eating disorder in adults and is the first drug approved for this indication, the Food and Drug Administration announced on Jan.
According to its current diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, the patent includes the use of the amphetamine prodrug lisdexamfetamine dimesylate (l-lysine-d-amphetamine) alone, or in combination with other pharmacologic therapies, for the treatment of Binge Eating Disorder.
Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study.
The treatment is called lisdexamfetamine dimesylate and is aimed initially at six to 18-year-olds.
Based on guidance from clinical experts, medications considered treatment for ADHD were methylphenidate, dextroamphetamine, mixed amphetamine salts, lisdexamfetamine, dexmethylphenidate, atomoxetine, clonidine, guanfacine, imipramine, nortriptyline, bupropion, and carbamazepine.
Generally, lisdexamfetamine dimesylate (Vyvanse) and methylphenidate (Ritalin), known as "stimulant" drugs, are prescribed for the condition.